IUPAC name
(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid
SMILES
CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
Compound class
Dietary Supplements; Micronutrients; Supplements; Omega-3 Fatty Acids;
Therapeutic area
EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.
Common name
Icosapent
IUPAC name
(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid
SMILES
CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O
INCHI
InChI=1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,13-12-,16-15-
FORMULA
C20H30O2
Common name
Icosapent
IUPAC name
(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid
Molecular weight
302.451
clogP
6.111
clogS
-3.317
HBond Acceptor
2
HBond Donor
1
Total Polar Surface Area
37.3
Number of Rings
0
Rotatable Bond
13
| Drug ID | Common name | Structure CAS | SMILE | Frequency |
|---|---|---|---|---|
| FDBF00004 | acetic acid |
|
CC(=O)O | 0.0687 |
| FDBF00022 | prop-1-ene |
|
CC=C | 0.0299 |
| FDBF00047 | propionic acid |
|
CCC(=O)O | 0.0395 |
| FDBF00061 | butyric acid |
|
CCCC(=O)O | 0.0131 |
| FDBF00074 | but-1-ene |
|
C(C)C=C | 0.0100 |
| FDBF00076 | penta-1,4-diene |
|
C=CCC=C | 0.0014 |
| FDBF00077 | (Z)-pent-2-ene |
|
C(C)C=CC | 0.0065 |
| FDBF00079 | (4Z)-hexa-1,4-diene |
|
CC=CCC=C | 0.0014 |
| FDBF00083 | (2Z,5Z)-hepta-2,5-diene |
|
C(C=CC)C=CC | 0.0014 |
| FDBF00084 | (2Z,5Z)-octa-2,5-diene |
|
C(C)C=CCC=CC | 0.0014 |
